Home Database Healthcare & PharmaVoyage Care

01/2022100%LBO

Voyage Care acquired by Wren House

UNITED KINGDOM Health Providers / Healthcare Facilities / Nursing Homes EV €500M–1.5bn

Context

Partners Group and Duke Street agreed to sell 100% of Voyage Care to Wren House Infrastructure Management, following approximately seven years of joint ownership since the 2014 acquisition alongside management. Key value creation initiatives delivered during the holding period include strategic management hires, continued investment in care quality, further development of specialist care disciplines, and capacity expansion through organic development and selective bolt-on acquisitions.

Voyage Care, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of 10x–18x, standing directly in line with the average observed in the Healthcare & Pharma sector (16.1x in 2022).

-> Deep-dive in Healthcare & Pharma market trends

Target

Voyage Care is a leading UK provider of specialist care and support services, founded in 1988 and headquartered in Lichfield. The company provides highly specialised care to people with learning and physical difficulties, brain injuries, autism, and other complex needs across the United Kingdom. A large majority of those supported by Voyage Care require high levels of care and support throughout their lives, making the company a critical long-term provider of essential social care services.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

15x–25x

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with Wren House

Other operations with Wren House
Date	Acquirer	Target	Country	Sector
07/2021	WREN HOUSE	ALMAVIVA SANTÉ	FRANCE	Clinics / Hospitals

Similar deals in Health Providers

Similar deals in Health Providers
Date	Acquirer	Target	Country	Sector
02/2022	PARTNERS GROUP	FOREFRONT DERMATOLOGY	UNITED STATES	Outpatient Care
02/2022	MEINE RADIOLOGIE	ALERIS - RADIOLOGY	SWEDEN	Radiology
12/2021	VIVALTO PARTNERS / IK PARTNERS / MACSF / ARKEA CAPITAL / BNP PARIBAS DEVELOPPEMENT	VIVALTO SANTÉ	FRANCE	Clinics / Hospitals
12/2021	RAMSAY HEALTH CARE	ELYSIUM HEALTHCARE	UNITED KINGDOM	Clinics / Hospitals
11/2021	CERBA HEALTHCARE	LABEXA	FRANCE	Labs (Biology)
10/2021	ARES / BPIFRANCE	POINT VISION	FRANCE	Ophthalmology
10/2021	IVC EVIDENSIA	VETONE	FRANCE	Vet Clinics
10/2021	THE CRANEMERE GROUP	OUTPATIENT IMAGING AFFILIATES	UNITED STATES	Radiology
09/2021	LIVINGBRIDGE	EVERLIGHT RADIOLOGY	UNITED KINGDOM	Radiology
08/2021	COLOSSEUM DENTAL GROUP	CURAEOS	NETHERLANDS	Dental Centers

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €250–500M

EBITDA range: €25–50M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Voyage Care by Wren House are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Acquirer: wren house

FAQ

What transaction does this page cover?

This page covers Wren House’s acquisition of 100% of Voyage Care, a British company specialised in Healthcare Facilities, in 2022, structured as a leveraged buyout (LBO).

How was the acquisition of Voyage Care by Wren House valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Voyage Care’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Voyage Care generated annual revenue estimated in the €250–500M range and EBITDA in the €25–50M bracket (FY 2022). Detailed financial figures are available to members.

How does the valuation of Voyage Care compare to benchmarks in the Healthcare & Pharma sector?

With an estimated multiple range of 10x - 18x, the transaction stands directly in line with historical averages for the Healthcare & Pharma sector (16.1x in 2022).

What sources support the information on this transaction?

Information on this transaction is supported by three corroborating sources: an official corporate announcement published by the parties, independent reporting from specialized financial publications, as well as a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.